Headquartered in San Carlos, CA Fiscal year ends December NYSE: ATTO attovia.com
Attovia Therapeutics is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. All of its product candidates are internally discovered using its proprietary ATTOBODY biparatopic biologics platform, which employs an evolution-driven, high-throughput process for rapid discovery and creation of diverse potential product candidates. The company's lead program, ATTO-1310, is an anti-IL-31 Fc-fusion protein in clinical development for chronic pruritic diseases including chronic pruritus of unknown origin, high-itch atopic dermatitis, and cholestatic pruritus. Its pipeline also includes ATTO-2306, a bispecific antibody targeting IL-31 and IL-13 for atopic dermatitis and other immune-mediated skin diseases, and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin α4β7 for inflammatory bowel disease. Earlier-stage programs include conditional 'AND-gated' bispecific immune cell survival blockers. Attovia trades on the Nasdaq Global Market under the ticker ATTO following its IPO in August 2026. Updated
Rate hike fears rattled markets heading into the Labor Day weekend, and Wall Street analysts responded with a flurry of bold calls on utilities, farm equipment giants, and a ticketing upstart that…
A newly public biotech is betting its entire future on a single antibody platform designed to silence the cytokine scientists call the itch cytokine, and its pipeline already stretches from skin disease…
Trey Thoelcke Attovia Therapeutics is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need.
The Wall Street consensus 12-month price target for ATTO is $42.20.
